The startup team is focusing on paper-based tests for detecting infections and antibiotic resistance for near-patient applications. BugSense has performed the first clinical validation with pilot studies to demonstrate urinary-tract-infection testing. 

The technology is primarily designed for clinical and near-patient applications, such as use in primary care settings and decentralized healthcare environments. Beyond clinical diagnostics, the platform has potential for future consumer-facing applications and screening use cases, pending further validation and regulatory approval. Upside potentials for BugSense include water quality testing.